Copertina

Letter: Refining the Understanding of Hepatic Steatosis and Cardiovascular Risk—Addressing Key Variables and Subgroup Analyses

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Changhu Sun, Zeping Chen, Lincheng Duan
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Letter: Addressing Gaps in Hospital‐Based Hepatitis C Screening—Insights and Recommendations
di: Zhen Deng, et al.
Pubblicazione: (2025)

Coronary Artery Disease and Major Adverse Cardiovascular Events in People With Hepatic Steatosis at Low Atherosclerotic Cardiovascular Disease Risk
di: Julia Karady, et al.
Pubblicazione: (2024)

Letter: Refining Mortality Estimates in Severe Alcohol‐Associated Hepatitis—Addressing Heterogeneity and Prognostic Assessment
di: Shupeng Zhao, et al.
Pubblicazione: (2025)

Letter: Refining Mortality Estimates in Severe Alcohol–Associated Hepatitis—Addressing Heterogeneity and Prognostic Assessment. Authors' Reply
di: Francisco Idalsoaga, et al.
Pubblicazione: (2025)

Letter: Addressing Gaps in Hospital‐Based Hepatitis C Screening—Insights and Recommendations. Authors' Reply'
di: Alberto Ferrarese, et al.
Pubblicazione: (2025)

Editorial: Beyond Viral Eradication—Cardiometabolic Risk and Cardiovascular Outcomes After SVR in Chronic Hepatitis C
di: Shun‐Ichi Wakabayashi, et al.
Pubblicazione: (2026)

Letter: Trajectories of Hepatic Function Markers Enable Early Prediction of Hepatic Recompensation
di: Benedikt Silvester Hofer, et al.
Pubblicazione: (2026)

Letter on ‘Meta‐Analysis: Mortality Trends and Risk Factors in Severe Alcohol‐Associated Hepatitis’—Authors' Reply
di: Francisco Idalsoaga, et al.
Pubblicazione: (2025)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis
di: Ewan Forrest, et al.
Pubblicazione: (2025)

Editorial: Residual HCC Risk After Hepatitis C Cure—Can Polygenic Risk Scores Refine Surveillance? Authors' Reply
di: Yu‐Sheng Lin, et al.
Pubblicazione: (2026)

Editorial: Beyond Viral Eradication—Cardiometabolic Risk and Cardiovascular Outcomes After SVR in Chronic Hepatitis C. Authors' Reply
di: Pei‐Chien Tsai, et al.
Pubblicazione: (2026)

Letter: Advancing Serologic Classification in Indeterminate Chronic Hepatitis B Through Dynamic and Integrated Frameworks
di: Chun‐Chieh Chen, et al.
Pubblicazione: (2025)

Letter: Late Diagnosis of Chronic Hepatitis B—Quantifying the Missed Opportunities and Clinical Consequences
di: Bi‐Yu Gao, et al.
Pubblicazione: (2025)

Letter: Addressing opioid exposure and associated harms in patients with IBD
di: Christian P. Selinger, et al.
Pubblicazione: (2024)

Letter on ‘Unveiling Drug‐Induced Autoimmune‐Like Hepatitis in Autoimmune Hepatitis Patients: A Multicenter Retrospective Study’
di: Muhammad Ibrahim Khalil, et al.
Pubblicazione: (2025)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis—Authors' Reply
di: Francisco Idalsoaga, et al.
Pubblicazione: (2025)

Editorial: Addressing Unmet Needs and Socioeconomic Disparity in Patients With Autoimmune Hepatitis
di: Seren Gedallovich, et al.
Pubblicazione: (2024)

Letter: Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
di: Zhidong Zhou, et al.
Pubblicazione: (2025)

Advanced Fibrosis and Cardiometabolic Risk Burden Increase Major Cardiovascular Events in Chronic Hepatitis C Patients With Steatotic Liver Disease After Viral Eradication
di: Pei‐Chien Tsai, et al.
Pubblicazione: (2025)

Letter: Statins for Cirrhosis: Are We Ready to Move From Cardiovascular Prophylaxis to Portal Pressure Management?
di: Abdulrahman Ismaiel
Pubblicazione: (2026)

Letter: Drug‐Induced Autoimmune‐Like Hepatitis—A Trigger on the Disease Spectrum. Authors' Reply
di: Pinelopi Arvaniti, et al.
Pubblicazione: (2025)

Letter on ‘Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis’: Authors' Reply
di: Lukas Burghart, et al.
Pubblicazione: (2026)

Letter: Pharmacotherapy for Alcohol Dependence in Cirrhosis—By Addressing One Issue Do We Create Another?
di: Andrew W. Nguyen, et al.
Pubblicazione: (2026)

Letter: Meta‐Analysis Critique: Refining the Association Between Helicobacter pylori and Eosinophilic Oesophagitis
di: Haleema Rahman
Pubblicazione: (2025)

Letter: Double‐Dose Hepatitis B Vaccination in IBD —A Step Forward in Protecting Immunosuppressed Patients
di: Luisa Bertin, et al.
Pubblicazione: (2026)

Letter: Timely Follow‐Up in Cirrhosis—A Key Public Health Intervention
di: Mo‐Yao Tan, et al.
Pubblicazione: (2024)

Letter: Statins for Cirrhosis: Are we Ready to Move From Cardiovascular Prophylaxis to Portal Pressure Management? Authors' Reply
di: Bernardo de Faria Moraes, et al.
Pubblicazione: (2026)

Letter: Does Serum HBV RNA Add Incremental Value for Hepatocellular Carcinoma Risk Stratification Beyond Established Predictors?
di: Yuanyan Sun, et al.
Pubblicazione: (2026)

Surviving Hepatitis C—Understanding Death and Survival Beyond Cure
di: Paul J. Clark, et al.
Pubblicazione: (2025)

Letter: Advancing Serologic Classification in Indeterminate Chronic Hepatitis B Through Dynamic and Integrated Frameworks—Authors' Reply
di: Rui Huang, et al.
Pubblicazione: (2025)

Letter: Enhancing Predictive Models for Paediatric Ulcerative Colitis—Addressing Socioeconomic, Environmental and Clinical Factors. Authors' Reply
di: Merle Claßen, et al.
Pubblicazione: (2024)

Letter: Risks of proton pump inhibitor treatment in cirrhotic patients
di: Jiamei Wang, et al.
Pubblicazione: (2024)

Letter: Geographic Transportability of Shingles Risk With Advanced IBD Therapies
di: Guofu Mao, et al.
Pubblicazione: (2026)

Letter: Reassessing Tenofovir Alafenamide Use Throughout Pregnancy—A New Horizon in Hepatitis B Therapy. Authors' Reply
di: Xingfei Pan, et al.
Pubblicazione: (2025)

Letter on “Immigration Factors and Monitoring of Chronic Hepatitis B Infection Among Foreign‐Born: The FOCUS‐HBV Multicentre Cohort”
di: Dong Hyun Kim, et al.
Pubblicazione: (2025)

Letter: Optimising Hepatitis B Vaccination in Inflammatory Bowel Disease – Expanding Strategies Beyond Double‐Dose Recombinant Vaccination
di: Yash Hegde, et al.
Pubblicazione: (2026)

Letter: The Hidden Truth of IBD Risk—From Antibiotics to Environmental Factors
di: Xueneng Yang, et al.
Pubblicazione: (2025)

Letter: Unmasking the Risks—The Need for Robust Data on Baclofen in Cirrhotic Patients
di: Zainab Salman
Pubblicazione: (2026)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR . Authors' Reply
di: Yu‐Sheng Lin, et al.
Pubblicazione: (2026)

Letter: Optimising public health policies to combat alcohol‐associated liver disease in youth—Addressing key methodological and regional challenges
di: Rui Zhang, et al.
Pubblicazione: (2024)